Sidawy AN, et al. Thromboangiitis obliterans. In: Rutherford's Vascular Surgery and Endovascular Surgery. 10th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 14, 2022.
Ami TR. Allscripts EPSi. Mayo Clinic. Dec. 22, 2022.
Le Joncour A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): A multicenter study of 224 patients. Journal of the American Heart Association. 2018; doi:10.1161/JAHA.118.010677.
Smoking and Buerger's disease. Centers for Disease Control and Prevention. https://www.cdc.gov/tobacco/campaign/tips/diseases/buergers-disease.html. Accessed Jan. 4, 2023.
Thromboangiitis obliterans (Buerger's disease). American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2019/10/21/15/05/thromboangiitis-obliterans. Accessed Jan. 4, 2023.
Cacione DG et al. Pharmacological treatment for Buerger's disease. Cochrane Database of Systematic Reviews. 2020; doi:10.1002/14651858.CD007411.pub5.
Galyfos G, et al. A systematic review and meta-analysis of early and late outcomes after endovascular angioplasty among patients with thromboangiitis obliterans and chronic limb ischemia. Journal of Vascular Surgery. 2022: doi:10.1016/j.jvs.2022.09.017.
Bergère G, et al. Effect of cannabis consumption on characteristics and evolution of thromboangitis obliterans. Vasa. 2021; doi:10.1024/0301-1526/a000948.
Heart attack prevention: Should I avoid secondhand smoke? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-attack/expert-answers/secondhand-smoke/faq-20058082. Accessed Jan. 17, 2023.
McBane RD II (expert opinion). Mayo Clinic. Feb. 7, 2023.